文献速递肺栓塞与肺血管病

抗凝血酶Ⅲ基因新突变致肺栓塞的临床与遗传分析

[Clinical and genetic analysis of pulmonary embolism induced by a novel gene mutation of the antithrombin Ⅲ gene].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2021-01-01

本文报道1例33岁男性急性中低危肺栓塞患者,ATⅢ活性持续低于50%,检出SERPINC1基因c.1148T>A(p.L383H)杂合错义突变,数据库与Mutation Taster确认其为新发致病突变(致病概率0.999 999 851 200 991)。患者那曲肝素钙联合华法林抗凝后咯血增多,换用利伐沙班后栓子逐渐吸收。结论认为该突变为新发致病突变,利伐沙班或可作为此类患者一线治疗。

要点

  • 年轻肺栓塞患者应筛查易栓症,ATⅢ活性持续低于50%提示遗传性ATⅢ缺乏。
  • SERPINC1基因c.1148T>A(p.L383H)为新发致病突变,补充遗传性ATⅢ缺乏突变谱。
  • 利伐沙班或可作为ATⅢ缺乏相关肺栓塞患者的一线治疗选择。

核心结论

  • SERPINC1基因c.1148T>A(p.L383H)为新发致病突变,补充和更新了遗传性ATⅢ缺乏症基因突变谱。
  • 新型口服抗凝药利伐沙班或可作为此类患者的一线治疗药物。

研究设计与样本

  • 病例报道:1例33岁男性胸痛患者,回顾其诊断和治疗过程。
  • 采用高通量二代基因测序检测7项易栓症基因的所有外显子及侧翼序列。
  • 使用基因数据库查询突变谱,并用Mutation Taster软件预测突变基因致病概率。

主要发现

  • 患者确诊为急性肺栓塞(中低危),病程中ATⅢ活性持续低于50%。
  • 给予那曲肝素钙联合华法林抗凝后咯血增多,更换为利伐沙班后栓子逐渐吸收。
  • 基因检测显示SERPINC1基因c.1148T>A(p.L383H)杂合错义突变。
  • 数据库与Mutation Taster确认该突变为新发致病突变,致病概率0.999 999 851 200 991,国内外尚未见报道。

关键数值与推荐

  • ATⅢ活性持续低于50%作为遗传性ATⅢ缺乏的提示指标。
  • SERPINC1基因c.1148T>A(p.L383H)杂合错义突变经Mutation Taster预测致病概率为0.999 999 851 200 991。

临床怎么用

  • 对年轻、无明确诱因的肺栓塞患者,应关注ATⅢ活性并考虑易栓症基因检测。
  • ATⅢ缺乏相关肺栓塞抗凝治疗中,若华法林联合低分子肝素出现出血不良反应,可考虑换用利伐沙班。

局限性

  • 本文为单例病例报道,结论的外推需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To improve the clinical management of acute pulmonary embolism caused by antithrombin Ⅲ (AT Ⅲ) deficiency through gene sequence analysis of the SERPINC1 gene. Methods: The diagnosis and treatment of a 33-year-old male patient with chest pain was reviewed. All exon sequences and flanking regions of 7 related genes of thrombophilia were subjected to detection by high-throughput next generation sequencing technology. The gene mutation was inquired in the gene database and the pathogenic probability of the mutant gene was predicted by Mutation Taster software. Results: The patient was diagnosed with acute pulmonary embolism (intermediate-low risk), with the ATⅢ activity less than 50%. Anticoagulation with nadroparin calcium combined with warfarin was administrated, but hemoptysis was aggravated, and then the medication was replaced by anticoagulant of rivaroxaban. In the end, the embolus was gradually absorbed. A heterozygous missense mutation of c.1148T>A (p.L383H) in the SERPINC1 gene was detected. The gene database and Mutation Taster confirmed the mutation as a new pathogenic mutation with the pathogenic probability of 0.999 999 851 200 991. Conclusions: C.1148T>A (p.L383H) is a novel pathogenic mutation in SERPINC1 gene that complements and updates the gene mutation spectrum of hereditary AT Ⅲ deficiency. The new oral anticoagulant rivaroxaban may be used as the first-line treatment for these patients. 目的: 通过基因(SERPINC1)序列分析提高对抗凝血酶Ⅲ(antithrombin Ⅲ,AT Ⅲ)缺乏导致的急性肺栓塞的临床诊治水平。 方法: 报道1例33岁男性胸痛患者的诊断和治疗过程,通过高通量二代基因测序检测7项易栓症基因的所有外显子及侧翼序列,使用数据库查询基因突变谱,使用Mutation Taster软件预测突变基因的致病概率。 结果: 该例患者确诊为急性肺栓塞(中低危),病程中发现患者AT-Ⅲ活性持续低于50%,给予那曲肝素钙联合华法林抗凝,患者咯血增多,更换用药为利伐沙班,栓子逐渐吸收。基因检测显示SERPINC1基因c.1148T>A(p.L383H)杂合错义突变,检索基因数据库并使用蛋白功能损伤预测软件确认该突变位点为新发致病突变,致病概率0.999 999 851 200 991,经文献检索目前国内外尚未见报道。 结论: SERPINC1基因c.1148T>A(p.L383H)为新发致病突变,补充和更新了遗传性AT Ⅲ缺乏症基因突变谱,新型口服抗凝药(利伐沙班)或可作为此类患者的一线治疗药物。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang, He, Ning, et al. [Clinical and genetic analysis of pulmonary embolism induced by a novel gene mutation of the antithrombin Ⅲ gene]. Zhonghua Jie He He Hu Xi Za Zhi. 2021. PMID: 34915622. doi:10.3760/cma.j.cn112147-20210326-00200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。